Timeliness of Clinic Attendance Is a Good Predictor of Virological Response and Resistance to Antiretroviral Drugs in HIV-Infected Patients

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Bastard, Mathieu ^a   Pinoges, Loretxu ^a   Balkan, Suna ^b   Szumilin, Elisabeth ^b   Ferreyra, Cecilia ^b   Pujades Rodriguez, Mar ^a  

^a EPICENTRE   (France)

^b MÉDECINS SANS FRONTIÈRES   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; BODY MASS; CD4 LYMPHOCYTE COUNT; CHILD; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRESCHOOL CHILD; SCHOOL CHILD; TREATMENT RESPONSE; TUBERCULOSIS; VIRUS LOAD;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; APPOINTMENTS AND SCHEDULES; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; VIRAL LOAD;

EID: 84868700255     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049091     Document Type: Article

References (32)

1. Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson AM, et al. (2008) Changes in the risk of death after HIV seroconversion compared with mortality in the general population. Jama 300: 51-59.
2. Ivers LC, Kendrick D, Doucette K, (2005) Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis 41: 217-224.
3. Abaasa AM, Todd J, Ekoru K, Kalyango JN, Levin J, et al. (2008) Good adherence to HAART and improved survival in a community HIV/AIDS treatment and care programme: the experience of The AIDS Support Organization (TASO), Kampala, Uganda. BMC Health Serv Res 8: 241.
4. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, et al. (2001) Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. Aids 15: 1181-1183.
5. Ford N, Darder M, Spelman T, Maclean E, Mills E, et al. (2010) Early adherence to antiretroviral medication as a predictor of long-term HIV virological suppression: five-year follow up of an observational cohort. PLoS One 5: e10460.
6. Lima VD, Harrigan R, Bangsberg DR, Hogg RS, Gross R, et al. (2009) The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr 50: 529-536.
7. World Health Organization (2003) Adherence to long-term therapy: Evidence for action. Geneva: World Health Organization. Available:http://apps.who.int/medicinedocs/en/d/Js4883e/.
8. Calmy A, Ford N, Hirschel B, Reynolds SJ, Lynen L, et al. (2007) HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis 44: 128-134.
9. Harries AD, Zachariah R, van Oosterhout JJ, Reid SD, Hosseinipour MC, et al. (2010) Diagnosis and management of antiretroviral-therapy failure in resource-limited settings in sub-Saharan Africa: challenges and perspectives. Lancet Infect Dis 10: 60-65.
10. Costagliola D, Barberousse C (2001) Comment mesurer l'observance? In: Collection sciences sociales et sida. ANRS P, editor. L'observance aux traitements contre le VIH/sida: mesure, déterminants, évolution. 33-42.
11. Farmer KC (1999) Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther 21: 1074-90; discussion 1073.
12. Ammassari A, Trotta MP, Murri R, Castelli F, Narciso P, et al. (2002) Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr 31 (Suppl 3):: S123-7.
13. Bastard M, Fall MB, Laniece I, Taverne B, Desclaux A, et al. (2011) Revisiting long-term adherence to highly active antiretroviral therapy in Senegal using latent class analysis. J Acquir Immune Defic Syndr 57: 55-61.
14. Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, et al. (2006) Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med 3: e438.
15. World Health Organization (2010) HIV drug resistance early warning indicators. World Health Organization indicators to monitor HIV drug resistance prevention at antiretroviral treatment sites. Geneva: World Health Organization. Available: http://www.who.int/hiv/topics/drugresistance/hiv_dr_early_warning_indicators.pdf.
16. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, et al. (2006) Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 367: 1335-1342.
17. Ferradini L, Laureillard D, Prak N, Ngeth C, Fernandez M, et al. (2007) Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia. Aids 21: 2293-2301.
18. Ahoua L, Guenther G, Pinoges L, Anguzu P, Chaix M-L, et al. (2009) Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda. BMC infectious diseases 9: 81. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2701435&tool=pmcentrez&rendertype=abstract. Accessed 2012 April 25.
19. Ahoua L, Guenther G, Rouzioux C, Pinoges L, Anguzu P, et al. (2011) Immunovirological response to combined antiretroviral therapy and drug resistance patterns in children: 1- and 2-year outcomes in rural Uganda. BMC pediatrics 11: 67. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3176156&tool=pmcentrez&rendertype=abstract. Accessed 2012 June 8.
20. Pujades-Rodríguez M, Schramm B, Som L, Nerrienet E, Narom P, et al. (2011) Immunovirological outcomes and resistance patterns at 4 years of antiretroviral therapy use in HIV-infected patients in Cambodia. Tropical medicine & international health: TM & IH 16: 205-213. Available: http://www.ncbi.nlm.nih.gov/pubmed/21087376. Accessed 2012 June 8.
21. World Health Organization (2010) Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach. 2010 revision. Geneva: World Health Organization. Available: http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf.
22. Liu TF, Shafer RW, (2006) Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 42: 1608-1618.
23. Shafer RW, (2006) Rationale and uses of a public HIV drug-resistance database. J Infect Dis 194 (Suppl):: S51-8.
24. Pujades-Rodriguez M, Balkan S, Arnould L, Brinkhof MA, Calmy A, (2010) Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries. Jama 304: 303-312.
25. Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, et al. (2006) Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. Jama 296: 679-690.
26. Maman D, Pujades-Rodriguez M, Nicholas S, McGuire M, Ecochard R, et al. (2011) Reaching 500 CD4 cells/μL is associated with higher survival after 9 months on ART in sub-Saharan African patients.
27. Pujades-Rodríguez M, Ferreyra C, Calmy A, Balkan S (2011) Failure on first line therapy and inequalities in switching to second line in adults treated in urban and rural ART programs: multicentric analysis in 28 MSF-supported African and Asian ART sites.
28. Bisson GP, Gross R, Bellamy S, Chittams J, Hislop M, et al. (2008) Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Med 5: e109.
29. Brennan AT, Maskew M, Sanne I, Fox MP, (2010) The importance of clinic attendance in the first six months on antiretroviral treatment: a retrospective analysis at a large public sector HIV clinic in South Africa. J Int AIDS Soc 13: 49.
30. El-Khatib Z, Katzenstein D, Marrone G, Laher F, Mohapi L, et al. (2011) Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa. PLoS One 6: e17518.
31. Ross-Degnan D, Pierre-Jacques M, Zhang F, Tadeg H, Gitau L, et al. (2010) Measuring adherence to antiretroviral treatment in resource-poor settings: the clinical validity of key indicators. BMC Health Serv Res 10: 42.
32. Cole TJ, Flegal KM, Nicholls D, Jackson AA, (2007) Body mass index cut offs to define thinness in children and adolescents: international survey. Bmj 335: 194.